הפודקאסט הופק בחסות חברת גיליאד סיאנסז

למידע נוסף ורשימת תופעות לוואי מלאה, יש לעיין בעלון לרופא כפי שמופיע באתר משרד הבריאות

לדווח תופעת לוואי

Trodelvy® (sacituzumab govitecan 200 mg) Powder for concentrate for solution for infusion.

Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Trodelvy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

הירשמו לקבלת עדכונים בנושאים שעלו בכתבה